An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension

Nature Medicine

Volumn 19, Issue 1, 2013, Pages 74-82

  Kim, Jongmin ^a   Kang, Yujung ^a   Kojima, Yoko ^a   Lighthouse, Janet K ^a   Hu, Xiaoyue ^a   Aldred, Micheala A ^b   McLean, Danielle L ^a   Park, Hyekyung ^a   Comhair, Suzy A ^b   Greif, Daniel M ^a   Erzurum, Serpil C ^b   Chun, Hyung J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APELIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; MICRORNA; MICRORNA 424; MICRORNA 503; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; SMOOTH MUSCLE FIBER;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DOWN-REGULATION; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; HUMANS; HYPERTENSION, PULMONARY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PULMONARY ARTERY; RATS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

EID: 84872078405     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3040     Document Type: Article

References (38)

1. Tuder, R.M., Marecki, J.C., Richter, A., Fijalkowska, I. & Flores, S. Pathology of pulmonary hypertension. Clin. Chest Med. 28, 23-42, vii (2007).
2. Humbert, M. et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 43, 13S-24S (2004).
3. Hassoun, P.M. et al. Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 54, S10-S19 (2009).
4. Schermuly, R.T., Ghofrani, H.A., Wilkins, M.R. & Grimminger, F. Mechanisms of disease: pulmonary arterial hypertension. Nat. Rev. Cardiol. 8, 443-455 (2011).
5. Izikki, M. et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J. Clin. Invest. 119, 512-523 (2009).
6. Eddahibi, S. et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation 113, 1857-1864 (2006).
7. Dewachter, L. et al. Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. Am. J. Respir. Crit. Care Med. 174, 1025-1033 (2006).
8. Chandra, S.M. et al. Disruption of the apelin-APJ system worsens hypoxia-induced pulmonary hypertension. Arterioscler. Thromb. Vasc. Biol. 31, 814-820 (2011).
9. Alastalo, T.P. et al. Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J. Clin. Invest. 121, 3735-3746 (2011).
10. Sheikh, A.Y. et al. In vivo genetic profiling and cellular localization of apelin reveals a hypoxia-sensitive, endothelial-centered pathway activated in ischemic heart failure. Am. J. Physiol. Heart Circ. Physiol. 294, H88-H98 (2008).
11. Hosoya, M. et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J. Biol. Chem. 275, 21061-21067 (2000).
12. Regard, J.B., Sato, I.T. & Coughlin, S.R. Anatomical profiling of G protein-coupled receptor expression. Cell 135, 561-571 (2008).
13. Goetze, J.P. et al. Apelin: a new plasma marker of cardiopulmonary disease. Regul. Pept. 133, 134-138 (2006).
14. Tuder, R.M., Groves, B., Badesch, D.B. & Voelkel, N.F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am. J. Pathol. 144, 275-285 (1994).
15. Masri, F.A. et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L548-L554 (2007).
16. Benisty, J.I. et al. Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest 126, 1255-1261 (2004).
17. Falcão-Pires, I. et al. Apelin decreases myocardial injury and improves right ventricular function in monocrotaline-induced pulmonary hypertension. Am. J. Physiol. Heart Circ. Physiol. 296, H2007-H2014 (2009).
18. Charo, D.N. et al. Endogenous regulation of cardiovascular function by apelin-APJ. Am. J. Physiol. Heart Circ. Physiol. 297, H1904-H1913 (2009).
19. Habata, Y. et al. Apelin, the natural ligand of the orphan receptor APJ, is abundantly secreted in the colostrum. Biochim. Biophys. Acta 1452, 25-35 (1999).
20. Chamorro-Jorganes, A. et al. MicroRNA-16 and microRNA-424 regulate cell-Autonomous angiogenic functions in endothelial cells via targeting vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1. Arterioscler. Thromb. Vasc. Biol. 31, 2595-2606 (2011).
21. Murakami, M. et al. The FGF system has a key role in regulating vascular integrity. J. Clin. Invest. 118, 3355-3366 (2008).
22. Stenmark, K.R., Meyrick, B., Galie, N., Mooi, W.J. & McMurtry, I.F. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L1013-L1032 (2009).
23. Taraseviciene-Stewart, L. et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 15, 427-438 (2001).
24. Tu, L. et al. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am. J. Respir. Cell Mol. Biol. 45, 311-322 (2011).
25. Masri, B., Morin, N., Cornu, M., Knibiehler, B. & Audigier, Y. Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells. FASEB J. 18, 1909-1911 (2004).
26. Eyries, M. et al. Hypoxia-induced apelin expression regulates endothelial cell proliferation and regenerative angiogenesis. Circ. Res. 103, 432-440 (2008).
27. Kälin, R.E. et al. Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. Dev. Biol. 305, 599-614 (2007).
28. del Toro, R. et al. Identification and functional analysis of endothelial tip cell-enriched genes. Blood 116, 4025-4033 (2010).
29. Kasai, A. et al. Apelin is a crucial factor for hypoxia-induced retinal angiogenesis. Arterioscler. Thromb. Vasc. Biol. 30, 2182-2187 (2010).
30. Kasai, A. et al. Retardation of retinal vascular development in apelin-deficient mice. Arterioscler. Thromb. Vasc. Biol. 28, 1717-1722 (2008).
31. Kidoya, H., Naito, H. & Takakura, N. Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood 115, 3166-3174 (2010).
32. Caruso, P. et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler. Thromb. Vasc. Biol. 30, 716-723 (2010).
33. Forrest, A.R. et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 24, 460-466 (2010).
34. Sarkar, S., Dey, B.K. & Dutta, A. MiR-322/424 and-503 are induced during muscle differentiation and promote cell cycle quiescence and differentiation by down-regulation of Cdc25A. Mol. Biol. Cell 21, 2138-2149 (2010).
35. Ghosh, G. et al. Hypoxia-induced microRNA-424 expression in human endothelial cells regulates HIF-Alpha isoforms and promotes angiogenesis. J. Clin. Invest. 120, 4141-4154 (2010).
36. Comhair, S.A. et al. Human primary lung endothelial cells in culture. Am. J. Respir. Cell Mol. Biol. 46, 723-730 (2012).
37. Aytekin, M. et al. High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L789-L799 (2008).
38. Chun, H.J. et al. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J. Clin. Invest. 118, 3343-3354 (2008).